

- [54] **CASEIN PHOSPHOPEPTIDE COMPOSITION**
- [75] **Inventors:** Gérard Brule; Loïc Roger, both of Rennes; Jacques Fauquant, Monfort; Michel Piot, Rennes, all of France
- [73] **Assignee:** Institut National de la Recherche Agronomique, Paris, France
- [*] **Notice:** The portion of the term of this patent subsequent to Jan. 22, 2002 has been disclaimed.
- [21] **Appl. No.:** 820,840
- [22] **Filed:** Jan. 22, 1986

4,303,580	12/1981	Hidalgo et al.	260/113
4,358,465	11/1982	Brule et al.	426/42
4,361,587	11/1982	Brule et al.	426/42
4,495,176	1/1985	Brule et al.	426/42 X

OTHER PUBLICATIONS

- Mellander, O., Pediatric Clinic and the Institute of Medical Chemistry, University of Uppsala, Sweden, 1949, pp. 247-255.
- West, D. W., Journal of Dairy Research, vol. 44, No. 2, 1977 (pp. 373-376).
- Nykkanen, et al., J. Nutr., vol. 110, 1980 (pp. 2141-2148).
- Brule, et al., J. Dairy Sci., vol. 62, 1979 (pp. 869-875).
- Roosen et al., Enzyme Microb. Technol., vol. 1, 1979 (pp. 122-124).

Primary Examiner—David M. Naff
Attorney, Agent, or Firm—Oblon, Fisher, Spivak, McClelland & Maier

Related U.S. Application Data

- [60] Continuation of Ser. No. 637,733, Aug. 6, 1984, abandoned, which is a continuation of Ser. No. 388,931, Jun. 16, 1982, Pat. No. 4,495,176, which is a division of Ser. No. 229,062, Jan. 28, 1981, Pat. No. 4,358,465.

Foreign Application Priority Data

- [30] Feb. 1, 1980 [FR] France 80 02281
- [51] **Int. Cl.⁴** C12P 21/06; C07K 1/00; A23J 3/02; A23C 23/00
- [52] **U.S. Cl.** 435/69; 424/127; 424/128; 426/42; 426/491; 435/272; 514/7; 530/352
- [58] **Field of Search** 426/34, 42, 657, 491; 435/69, 272; 424/127, 128, 131, 140, 145, 147, 177; 530/352; 514/7

[57] **ABSTRACT**

A casein phosphopeptide composition is prepared containing less than 4% phenylalanine, tyrosine and tryptophan, greater than 8% and less than 20% serine, a ratio of Ca+Mg+P/N_T greater than 0.2, wherein N_T is the total nitrogen content times 6.38, and free amino acids of less than 3%. The composition is useful as an ailment for dietetic or therapeutic nutrition or as a medicament. Salts of the phosphopeptides may be formed from macroelements such as calcium and/or magnesium and/or from oligoelements such as iron, zinc and copper. The composition is produced by proteolytic enzyme hydrolysis of a casein-based material, and using ultrafiltration and aggregation with a bivalent cation salt to isolate the phosphopeptide composition.

References Cited

U.S. PATENT DOCUMENTS

- 3,974,294 8/1976 Schmile et al. 426/657 X
- 4,172,072 10/1979 Ashmead 260/113 X

11 Claims, 2 Drawing Sheets